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Abstract
The Rome diagnostic criteria for the
functional bowel disorders and functional
abdominal pain are used widely in re-
search and practice. A committee consen-
sus approach, including criticism from
multinational expert reviewers, was used
to revise the diagnostic criteria and
update diagnosis and treatment recom-
mendations, based on research results.
The terminology was clarified and the
diagnostic criteria and management rec-
ommendations were revised. A functional
bowel disorder (FBD) is diagnosed by
characteristic symptoms for at least 12
weeks during the preceding 12 months in
the absence of a structural or biochemical
explanation. The irritable bowel syn-
drome, functional abdominal bloating,
functional constipation, and functional
diarrhea are distinguished by symptom-
based diagnostic criteria. Unspecified
FBD lacks criteria for the other FBDs.
Diagnostic testing is individualized, de-
pending on patient age, primary symptom
characteristics, and other clinical and
laboratory features. Functional abdomi-
nal pain (FAP) is defined as either the
FAP syndrome, which requires at least six
months of pain with poor relation to gut
function and loss of daily activities, or
unspecified FAP, which lacks criteria for
the FAP syndrome. An organic cause for
the pain must be excluded, but aspects of
the patient’s pain behavior are of primary
importance. Treatment of the FBDs relies
upon confident diagnosis, explanation,
and reassurance. Diet alteration, drug
treatment, and psychotherapy may be
beneficial, depending on the symptoms
and psychological features.
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The functional bowel disorders and functional
abdominal pain are common and cause much
suVering. As these entities are identified by
symptoms and patient care is highly individual-
ized, a symptom-based classification has great
importance, particularly for use in clinical trials
(table 1).
The 1998 Working Team assessed the termi-
nology and results of relevant clinical research
in order to revise the diagnostic criteria,
comment further on diagnosis, and summarize
treatment recommendations.
C. Functional bowel disorders
A functional bowel disorder (FBD) is a
functional gastrointestinal disorder with symp-
toms attributable to the mid or lower gastro-
intestinal tract, including the irritable bowel
syndrome (IBS), functional abdominal bloat-
ing, functional constipation, functional di-
arrhea, and unspecified functional bowel
disorder.
Subjects with a FBD may be divided into the
following groups:
Abbreviations used in this paper: FBD, functional
bowel disorder; IBS, irritable bowel syndrome; FAPS,
functional abdominal pain syndrome.




A3. Functional chest pain of presumed esophageal origin
A4. Functional heartburn
A5. Functional dysphagia









C1. Irritable bowel syndrome
C2. Functional abdominal bloating
C3. Functional constipation
C4. Functional diarrhea
C5. Unspecified functional bowel disorder
D. Functional abdominal pain
D1. Functional abdominal pain syndrome
D2. Unspecified functional abdominal pain
E. Biliary disorders
E1. Gall bladder dysfunction
E2. Sphincter of Oddi dysfunction
F. Anorectal disorders
F1. Functional fecal incontinence
F2. Functional anorectal pain
F2a. Levator ani syndrome
F2b. Proctalgia fugax
F3. Pelvic floor dyssynergia
G. Functional pediatric disorders
G1. Vomiting
G1a. Infant regurgitation
G1b. Infant rumination syndrome
G1c. Cyclic vomiting syndrome
G2. Abdominal pain
G2a. Functional dyspepsia
G2b. Irritable bowel syndrome




G4. Disorders of defecation
G4a. Infant dyschezia
G4b. Functional constipation
G4c. Functional fecal retention
G4d. Non-retentive fecal soiling
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(1) non-patients: those who have never sought
health care for the FBD;
(2) patients: those who have sought care for the
FBD; (a) incident cases: those who have
sought care for the FBD for the first time in
the past year; (b) prevalent cases: those who
have ever sought care for the FBD.
Symptoms of a FBD must have been present
for 12 weeks or more within the past 12
months; the 12 weeks need not be consecutive.
The diagnosis always presumes the absence of
a structural or biochemical explanation for the
symptoms.
The Working Team changed the definitions
of IBS, functional abdominal bloating and
functional constipation from a “disorder” to
“disorders” to acknowledge multiple patho-
physiologic possibilities. For IBS, “discomfort”
was added to “pain” to broaden symptom
description, and “distension” was deleted.
To clarify how discomfort and pain are tem-
porally related to a change in frequency and
form of stool, “onset” was added to the relevant
symptom features. The symptom criteria for
IBS were changed (a) by designating the non-
pain-related, the second part of the previous
criteria, as nonessential due to their poor clus-
tering in factor analyses1 2; (b) their lesser
prevalence in men3; and (c) the partial duplica-
tion in the retained, pain-related criteria.
Furthermore, these symptoms were clarified by
replacing the term “altered” with “abnormal.”
The criteria for functional constipation were
expanded due to the overlap between it and the
functional anorectal disorders (see Functional
disorders of the anus and rectum).
C1. Irritable bowel syndrome
IBS comprises a group of functional bowel dis-
orders in which abdominal discomfort or pain
is associated with defecation or a change in
bowel habit, and with features of disordered
defecation.
Surveys of Western populations have re-
vealed IBS in 15–20% of adolescents and
adults, with a higher prevalence in women; the
prevalence is variable in other populations.4
IBS has a chronic relapsing course and overlaps
with other functional gastrointestinal
disorders.5 It accounts for high direct medical
expenses6 and indirect costs, including absen-
teeism from work.5
DIAGNOSTIC CRITERIA
At least 12 weeks, which need not be
consecutive, in the preceding 12 months of
abdominal discomfort or pain that has two
of three features:
(1) Relieved with defecation; and/or
(2) Onset associated with a change in
frequency of stool; and/or
(3) Onset associated with a change in form
(appearance) of stool.
The following symptoms cumulatively sup-
port the diagnosis of IBS:
+ abnormal stool frequency (for research pur-
poses “abnormal” may be defined as >3/day
and <3/week);
+ abnormal stool form (lumpy/hard or loose/
watery stool);
+ abnormal stool passage (straining, urgency,
or feeling of incomplete evacuation);
+ passage of mucus;
+ bloating or feeling of abdominal distension.
These symptoms can be used to subclassify
patients with predominant diarrhea or consti-
pation for entry into clinical trials (table 2).
DIAGNOSTIC COMMENTS
The validity of the symptom criteria is
supported by patient studies,3 7 8 factor analy-
ses on non-patients1 2 and long term patient
follow up.9 The history may also reveal
postprandial symptom exacerbation,10 and oc-
casionally, incontinence and nocturnal pain.
Symptom worsening during menses and other
features can falsely suggest a gynecologic
explanation for “chronic pelvic pain.”11 Other
non-gastrointestinal somatic symptoms are
common.5 Colonic transit time can be esti-
mated by rating self-reported stool appearance
according to a stool form scale.12 Fever, rectal
bleeding, or weight loss require consideration
of another disorder.13 Abdominal examination
reveals no abnormality. Large bowel structural
examination is recommended to support a
symptom-based diagnosis. The choice of such
examinations should be guided by the age and
gender of the patient, the nature and duration
of symptoms, and other factors.8 14
TREATMENT RECOMMENDATIONS
A confident diagnosis, explanation, and reas-
surance are vital therapeutic tools. A graded,
multicomponent approach is advised, depend-
ing on the dominant symptoms, their severity
and psychosocial factors.4 Although rigorous
therapeutic trials are scarce, popular therapy
includes the use increased dietary fiber such as
wheat bran or bulking agents for constipation,
loperimide or diphenoxylate for diarrhea, and
anticholinergic/antispasmodic agents or low-
dose antidepressants for pain.4 Psychological or
behavioral treatments may help some patients.
C2. Functional abdominal bloating
Functional abdominal bloating comprises a
group of functional bowel disorders which are
dominated by a feeling of abdominal fullness or
bloating and without suYcient criteria for
another functional gastrointestinal disorder.
Few studies adequately separate bloating
from IBS and other functional disorders, but it
occurs in about 15% of community-based
Table 2 Supportive symptoms of the irritable bowel
syndrome
1. Fewer than three bowel movements a week
2. More than three bowel movements a day
3. Hard or lumpy stools
4. Loose (mushy) or watery stools
5. Straining during a bowel movement
6. Urgency (having to rush to have a bowel movement)
7. Feeling of incomplete bowel movement
8. Passing mucus (white material) during a bowel movement
9. Abdominal fullness, bloating or swelling
Diarrhea-predominant
1 or more of 2, 4, or 6 and none of 1, 3, or 5
Constipation-predominant
1 or more of 1, 3, or 5 and none of 2, 4, or 6
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populations, usually with a female predomi-
nance.15 16
DIAGNOSTIC CRITERIA
At least 12 weeks, which need not be
consecutive, in the preceding 12 months of:
(1) Feeling of abdominal fullness, bloating,
or visible distension; and
(2) InsuYcient criteria for a diagnosis of
functional dyspepsia, IBS, or other
functional disorder.
DIAGNOSTIC COMMENTS
Functional bloating is usually absent on awak-
ening and worsens throughout the day. It may
be intermittent and related to ingestion of spe-
cific foods. Excessive burping or farting may be
present, but these are not necessarily related to
the bloating. Diarrhea, weight loss, or nutri-
tional deficiency should alert the physician to
investigate for another disorder.
TREATMENT RECOMMENDATIONS
There is no proved eVective therapy for
functional bloating, and its cause is unknown,
so only education and reassurance are recom-
mended. The common practice of restricting
certain “gas-forming” foods may be beneficial
but even patients with confirmed lactase
deficiency can drink 250 ml milk with no or
negligible bloating.17
C3. Functional constipation
Functional constipation comprises a group of
functional disorders which present as persist-
ent diYcult, infrequent or seemingly incom-
plete defecation.
Constipation occurs in up to 20% of popula-
tions, depending on demographic factors, sam-
pling and the definition used. It is more
common in women and is usually found to
increase with age.5 18
DIAGNOSTIC CRITERIA
At least 12 weeks, which need not be
consecutive, in the preceding 12 months of
two or more of:
(1) Straining in >1/4 defecations;
(2) Lumpy or hard stools in >1/4 defeca-
tions;
(3) Sensation of incomplete evacuation in
>1/4 defecations;
(4) Sensation of anorectal obstruction/
blockade in >1/4 defecations
(5) Manual maneuvers to facilitate >1/4
defecations (e.g., digital evacuation,
support of the pelvic floor); and/or
(6) <3 defecations/week.
Loose stools are not present, and there are
insuYcient criteria for IBS.
DIAGNOSTIC COMMENTS
The physician should clarify what the patient
means by constipation, as patients describe it in
various ways.19 Many, if not most patients actu-
ally have the rectal symptoms of IBS with or
without lumpy stools.20 Evaluation of the
patient’s general health, psychological status,
use of constipating medications, dietary fiber
intake, and medical illnesses (e.g., hypo-
thyroidism) is important. In patients who do
not respond to fiber supplementation, meas-
urements of whole gut transit time21 and
anorectal function22 may be indicated to place
them in a physiological subgroup.
TREATMENT RECOMMENDATIONS
Dietary fiber increases fecal bulk by providing
indigestible matter and promoting fecal water
holding and bacterial proliferation.23 Other
useful bulking agents include psyllium, methyl-
cellulose, and calcium polycarbophil. Severely
constipated patients may respond to polyethe-
lene glycol solution.24 Otherwise, stimulant
laxatives such as bisacodyl, sodium picosul-
phate, or sennosides may be tried. Specific
treatment for patients in the anorectal dysfunc-
tion subgroup is discussed in Functional disor-
ders of the anus and rectum.
C4. Functional diarrhea
Functional diarrhea is continuous or recurrent
passage of loose (mushy) or watery stools with-
out abdominal pain.
A British population survey of stool form (a
scale previously validated against symptoms
and transit time12) revealed liquid stools were
the predominant type described by 5.3% of
men and 4.3% of women.25 Liquid stools were
more common in women under 50 years of age
than in older women.
DIAGNOSTIC CRITERIA
At least 12 weeks, which need not be
consecutive, in the preceding 12 months of:
(1) Liquid (mushy) or watery stools;
(2) Present >3/4 of the time; and
(3) No abdominal pain.
DIAGNOSTIC COMMENTS
Pseudodiarrhea (frequent defecation and ur-
gency with solid stools) must be distinguished
from diarrhea. Chronic diarrhea without pain
is caused by many diseases indistinguishable by
history, which should be excluded by diagnos-
tic testing. Basic evaluation includes routine
blood and stool tests plus sigmoidoscopy with
biopsy. Features atypical for a functional disor-
der (e.g., large volume stools, rectal bleeding,
nutritional deficiency, and weight loss) call for
more extensive studies of intestinal structure
and function—for example, radiography, duo-
denal biopsy, and serum hormone assay.
TREATMENT RECOMMENDATIONS
Discussion of possible psychosocial factors,
symptom explanation, and reassurance are
important. Restriction of foods which seem
provocative may help. Empiric antidiarrheal
therapy (e.g., diphenoxylate or loperimide) is
usually eVective, especially if taken prophylac-
tically, such as before meals. The occasional
patient responds to cholestyramine. Fortu-
nately, spontaneous remissions are common.26
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C5. Unspecified functional bowel
disorder
An unspecified functional bowel disorder is
defined as functional bowel symptoms that
do not meet criteria for the previously
defined categories.
D. Functional abdominal pain
Functional abdominal pain describes continu-
ous, nearly continuous, or frequently recurrent
pain localized in the abdomen but poorly
related to gut function.
Functional abdominal pain is divided into
two categories.
D1. Functional abdominal pain
syndrome
Functional abdominal pain syndrome (FAPS),
also called “chronic idiopathic abdominal
pain” or “chronic functional abdominal pain,”
describes pain for at least six months that is
poorly related to gut function and is associated
with some loss of daily activities.
FAPS occurs in 1.7% of people, mainly
women, and is associated with significant
absenteeism from work and physician visits.5
Over time, patients with FAPS tend to have
many specialist referrals, diagnostic tests and
major abdominal and pelvic operations.27
DIAGNOSTIC CRITERIA
At least six months of:
(1) Continuous or nearly continuous ab-
dominal pain; and
(2) No or only occasional relation of pain
with physiological events (e.g., eating,
defecation or menses); and
(3) Some loss of daily functioning; and
(4) The pain is not feigned (e.g., malinger-
ing); and
(5) InsuYcient criteria for other functional
gastrointestinal disorders that would
explain the abdominal pain.
DIAGNOSTIC COMMENTS
Aspects of the patient’s pain behavior are of
primary importance.27 Typically, the pain is
described in emotional or bizarre terms,
involves a large anatomic area, is associated
with other painful symptoms, and is part of a
continuum of painful experiences over many
years. Usually, patients urgently report pain as
extremely intense, and they request many diag-
nostic studies or surgery, focus primarily on the
illness, and relentlessly seek pain relief and
validation that the pain is “organic.” They often
ignore or deny a role for psychosocial contribu-
tions and absolve personal responsibility for
self-management, while placing high expecta-
tions for relief on the physician. Pain behavior
may diminish when the patient is distracted or
not aware of being observed. A spouse or par-
ent may be so aVected by the patient’s illness as
to report the history. Requests for narcotics are
common. FAPS may co-exist with a structural
disease (e.g., chronic pancreatitis) or FBD
(e.g., IBS). The observation of a lack auto-
nomic arousal, eye closure during abdominal
examination, and diminished pain behavior
with stethoscope application to the abdomen
are typical. Multiple abdominal scars are com-
mon.
TREATMENT RECOMMENDATIONS
Management depends on an eVective doctor–
patient relationship,27 including reasonable
goals, regular appointments and, in some cases,
concurrent psychological treatment. Analge-
sics are ineVective, and narcotics should be
avoided. Concurrent depression should be
treated. Low doses of antidepressants can
reduce pain as well as insomnia. Anxiolytic
therapy, if used at all, should be limited in
duration. Various types of psychotherapy have
been tried without critical evaluation. A multi-
disciplinary pain management program may be
the most promising approach.28
D2. Unspecified functional abdominal
pain
Unspecified functional abdominal pain is
functional abdominal pain which fails to
meet criteria for FAPS (D1).
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